FGAM
KZR

Financial Gravity Asset Management’s Kezar Life Sciences KZR Stock Holding History

Financial Gravity Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$129 – 1424
2022
Q4 		$129 Buy
+1
New +$74 ﹤0.01% 1068

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Financial Gravity Asset Management's KZR Position: Q1 2023 in Review

Financial Gravity Asset Management sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 1 share — an estimated $129 sold.

Financial Gravity Asset Management first reported a position in KZR in Q4 2022 and held it in 1 quarter. The position peaked at $129 in Q4 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Financial Gravity Asset Management reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Kezar Life Sciences share in Q1 2023, an estimated $129.
  • Financial Gravity Asset Management first reported a position in Kezar Life Sciences in Q4 2022 and held it in 1 quarter.
  • Financial Gravity Asset Management's Kezar Life Sciences position peaked at $129 in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Financial Gravity Asset Management's 13F filing for Q1 2023, filed 12 May 2023.